Dabigatran Etexilate RE-CIRCUIT and RE-DUAL Clinical Trials | Boehringer Ingelheim

Clinically meaningful research with Pradaxa®

Two clinical trials compared the use of Pradaxa® vs standard of care in 2 patient populations. Watch video summaries currently appearing on the New England Journal of Medicine website.

RE-CIRCUIT® Trial

This clinical trial examined results in patients taking either Pradaxa® 150 mg or warfarin while undergoing ablation for atrial fibrillation (AF).

RE-DUAL PCITM Trial

This clinical trial compared outcomes in patients taking the following regimens after undergoing PCI (percutaneous coronary intervention) with stenting: Pradaxa® 150 mg or 110 mg BID + P2Y12 inhibitor vs warfarin + P2Y12 inhibitor.